Medicine Grand Rounds - Cardiovascular Safety of Urate-Lowering Drugs in Gout

Dartmouth Health Continuing Education for Professionals Home, Medicine Grand Rounds - Cardiovascular Safety of Urate-Lowering Drugs in Gout, 12/10/2021 8:00:00 AM - 12/10/2024 9:00:00 AM, Participants in Medicine Grand Rounds will be able to identify the most current treatment guidelines, innovations, and standards of practice, and apply them to improve the care of individual patients, promote health and wellness in the population, and achieve clinical quality and safety goals. These educational activities are grounded in principles of health equity, evidence based medicine, inter-professional teamwork, patient-centered care, and respect for human dignity.

Presenter
Seoyoung C. Kim, MD, ScD, MSCE
Associate Professor of Medicine, Harvard Medical School 
Director, Program in Rheumatologic, Immunologic, and Musculoskeletal PharmacoEpidemiology
Division of Pharmacoepidemiology & Pharmacoeconomics
Division of Rheumatology, Inflammation, and Immunity
Brigham and Women's Hospital

About our Presenter
Dr. Seoyoung Kim graduated from the College of Medicine at Hanyang University in Seoul, Korea and completed residency training in Internal Medicine at State University of New York at Buffalo. She finished her fellowship training in Rheumatology at the University of Pennsylvania and Brigham and Women’s Hospital. She received a master’s degree in Clinical Epidemiology at the University of Pennsylvania and a doctoral degree in Epidemiology at Harvard T.H. Chan School of Public Health. Her research focuses on comparative safety and effectiveness of medications for the rheumatic diseases as well as health services/outcomes research in rheumatology.

Learning Outcome(s)
At the conclusion of this learning activity, participants will be able to discuss the risk of cardiovascular disease and mortality in patients with gout as well as current guidelines for the management of gout including available data on the cardiovascular safety of urate-lowering drugs.

Disclosure
The following activity director(s), planning committee member(s), speaker(s), author(s) or anyone in a position to control the content for this activity have reported the following financial relationship(s)* with ineligible company(ies)**. All of the relevant financial relationships listed for these individuals have been mitigated.

* Richard I. Rothstein, MD ~ has research support from Fractyl and is on the Scientific Advisory Board for Allurion.

* Seoyoung C. Kim, MD, ScD, MSCE ~ has research grants from AbbVie, Roche, Pfizer, and Bristol-Myers Squibb.

Other planning committee member(s), speaker(s), activity director(s), author(s) or anyone in a position to control the content for this activity report NO financial relationship(s)* with any ineligible company(ies)**. 

* A “financial relationship" includes employee, researcher (named as the PI), consultant, advisor, speaker, independent contractor (including contracted research), royalties or patent beneficiary, executive role, and/or an ownership interest (not including stocks owned in a managed portfolio).

** An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.

Bibliographic Material
See presentation for bibliographic sources to allow for further study.